Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

SultanK May. 22 at 5:36 AM

$ABCL Check the # of short and short ratio to cover it.. FWIW, shorts are paying 11.6% at IB on the borrowed shares.. Eventually, some one will be paying the price.. Sooner or later.. extract from CC transcript In January, on the strength of early biomarker and safety data, we announced that our lead program, ABCL-635, had moved into Phase II testing. By far, the most important data readout in 2026 will be the top-line readout of this study, anticipated in Q3. Note: Q3 is not too far away..

0 · Reply

Plutten1973 May. 22 at 4:06 AM

$ABCL

0 · Reply

Stocktradesmoon May. 22 at 3:40 AM

$ABCL $ABCL Called the accumulation phase. The stock is coming back. When I posted about treating the post-Phase 1 sell off as an opportunity, the thesis was simple. The data wasn’t bad. The market just wanted efficacy numbers that Phase 1 isn’t designed to deliver. Everything that actually mattered came back clean. And since then the story has only gotten stronger. Phase 1 data confirmed zero liver toxicity across all doses from 30mg to 900mg. Zero serious adverse events. Strong NK3R target engagement confirmed. Half life of approximately 24 days supporting once monthly dosing. Phase 2 already enrolling. Q3 topline data on track.

0 · Reply

Stocktradesmoon May. 22 at 3:40 AM

$ABCL 2) Then on May 18, an insider made a fresh share purchase. Goldman sitting on 4.3M shares. Baker Bros increased from 9.1% to 10.8% the day before the readout. Cantor Fitzgerald initiated Overweight. Evan Seigerman reiterated Buy with $7 price target citing strong Phase 1 data and platform strength. Analyst consensus sitting around $9.00 against a current price that’s been recovering. Revenue doubled year over year in Q1. Net loss narrowed. $655M in liquidity. Four programs in clinical or IND enabling stage. ABCL575 Phase 1 data coming H2 2026. The pipeline isn’t #ABCL635 alone. Q3 is still the moment. The setup going into it keeps getting cleaner. 😉

0 · Reply

8008track May. 22 at 1:01 AM

$ABCL pretend you had $1M to invest and you could only buy stocks. How much of that would you invest in $ABCL?

0 · Reply

manojaggarwal May. 21 at 10:22 PM

$ABCL

1 · Reply

tranq19 May. 21 at 10:08 PM

$ABCL so few shares actually available to trade, never seen anything like it. Carl owns a ridiculous percentage, baker bros, me, etc…50k shares here across family and not selling short of 25, maybe never. Just think if you sold NVDA in the early days…

1 · Reply

Stocktradesmoon May. 21 at 9:44 PM

$ABCL $ABCL has swung wildly up and down over the last 18 months. This could be the best day in that time. Is it possible the big players have all loaded their bags and are ready to make it fly? It sure feels that way. Is blue sky here …..

0 · Reply

Stocktradesmoon May. 21 at 9:33 PM

$ABCL $ABCL holders today… more to come!

0 · Reply

Ckkung71 May. 21 at 7:54 PM

$ABCL Hope what we see is bank of America conference people are baying. After all good stuff lately it most sooner or later be seen in reality.

0 · Reply

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T10:58:11.000Z - 9 days ago

AbCellera price target raised to $8 from $7 at Stifel

May 11, 2026, 7:08 PM EDT - 10 days ago

AbCellera Biologics Q1 Earnings Call Highlights

2026-05-11T21:58:40.000Z - 10 days ago

AbCellera Biologics options imply 9.7% move in share price post-earnings

May 11, 2026, 5:00 PM EDT - 10 days ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 10 days ago

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 10 days ago

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 10 days ago

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 4:05 PM EDT - 10 days ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 14 days ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

2026-05-05T10:36:31.000Z - 16 days ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

Apr 29, 2026, 8:00 AM EDT - 22 days ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 22 days ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 21, 2026, 1:30 PM EDT - 4 weeks ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 4 weeks ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

2026-04-09T20:10:26.000Z - 6 weeks ago

AbCellera initiated with a Buy at JonesResearch

Apr 1, 2026, 4:05 PM EDT - 7 weeks ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 2 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 2 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Slides: Q4 2025

2026-02-24T21:15:21.000Z - 3 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year

Feb 24, 2026, 4:05 PM EST - 3 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 4 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 4 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:00 AM EST - 4 months ago

AbCellera Biologics Slides: Corporate presentation

2026-01-12T14:36:23.000Z - 4 months ago

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

Jan 12, 2026, 9:00 AM EST - 4 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

2025-12-18T14:20:19.000Z - 5 months ago

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

BRKR

Dec 18, 2025, 9:00 AM EST - 5 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 5 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 6 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 6 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 6 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

2025-11-07T11:16:20.000Z - 6 months ago

AbCellera downgraded to Market Perform from Outperform at Leerink

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 7 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

2025-09-10T13:20:54.000Z - 9 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX

Sep 10, 2025, 9:07 AM EDT - 9 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 9 months ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

2025-08-27T13:20:26.000Z - 9 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 9 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

2025-08-08T13:26:29.000Z - 10 months ago

AbCellera price target raised to $7 from $5 at BMO Capital

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 1, 2025, 7:00 AM EDT - 10 months ago

AbCellera Biologics Slides: Corporate Presentation

Jul 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

2025-07-07T10:40:33.000Z - 11 months ago

AbCellera assumed with an Outperform at Leerink

2025-06-11T13:45:23.000Z - 1 year ago

Unusually active option classes on open June 11th

AFRM BILI FXE LAES PCG QUBT RGTI

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 17, 2024, 11:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 10, 2024, 3:20 PM EDT - 2 years ago

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 16, 2024, 10:00 AM EDT - 2 years ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 20, 2024, 11:15 AM EDT - 2 years ago

AbCellera Biologics Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

SultanK May. 22 at 5:36 AM

0 · Reply

Plutten1973 May. 22 at 4:06 AM

$ABCL

0 · Reply

Stocktradesmoon May. 22 at 3:40 AM

0 · Reply

Stocktradesmoon May. 22 at 3:40 AM

0 · Reply

8008track May. 22 at 1:01 AM

$ABCL pretend you had $1M to invest and you could only buy stocks. How much of that would you invest in $ABCL?

0 · Reply

manojaggarwal May. 21 at 10:22 PM

$ABCL

1 · Reply

tranq19 May. 21 at 10:08 PM

1 · Reply

Stocktradesmoon May. 21 at 9:44 PM

0 · Reply

Stocktradesmoon May. 21 at 9:33 PM

$ABCL $ABCL holders today… more to come!

0 · Reply

Ckkung71 May. 21 at 7:54 PM

$ABCL Hope what we see is bank of America conference people are baying. After all good stuff lately it most sooner or later be seen in reality.

0 · Reply

tradersunion353 May. 21 at 6:15 PM

$ABCL Day traders I understand if you celebrate it makes sense. What are the longs celebrating for? It should have been trading at 6 to 7 dollars by now. such a boring lazy Overhyped junk

2 · Reply

Ed_Ng May. 21 at 6:07 PM

$ABCL if you missed talking profit at 5.6, you still have time.

0 · Reply

tradersunion353 May. 21 at 5:51 PM

$ABCL Overhyped underperforming junk should have been traidng minium of $6 -$8 dollars after phase 1 data. POS is struggling hold 5 dollars Meanwhile clowns who are married to this scam are cheerleading for lousy little 12% bump Hello.. this POS is down 80% for last 5 years..

0 · Reply

Ed_Ng May. 21 at 4:56 PM

$ABCL you're welcome 🤗! Time will tell. I never wrong trading this POS!

1 · Reply

Trigga_tha_Gambler May. 21 at 4:53 PM

$ABCL In at 5.11

0 · Reply

NJgolfer May. 21 at 4:35 PM

$ABCL up 28% since highlighting the volume move. Most of the time, volume proceeds price action.

1 · Reply

Olivia_Strickland May. 21 at 4:30 PM

$ABCL up 16% on a 0.85x avg vol day, which is the kind of breakout where the room is empty but somebody clearly didn't get the memo. biotech ripping into +65% on the quarter without the usual ADC/oncology headline blast feels off, the tape is moving like there's a reason and the news flow just hasn't caught up. something specific is doing the work here and it's not what's trending on my feed. who else has eyes on this and what are you seeing that I'm not? where the volume showed up: https://tapeboard.com/chart/ABCL?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=abcl-bk-up-vol

0 · Reply

tranq19 May. 21 at 4:09 PM

$ABCL phase 2, started in January, given they were measuring at four weeks. Do you really think they don’t already know what the results are gonna look like

0 · Reply

Ed_Ng May. 21 at 4:09 PM

$ABCL add more to short position. Easy money!

4 · Reply

snowPOW May. 21 at 4:08 PM

$ABCL too small of a market cap. To 20B

0 · Reply

Quadruple_Double May. 21 at 4:08 PM

$ABCL will either spike to $6 by EOD or dump back. No in between. Just a prediction.

1 · Reply

snowPOW May. 21 at 4:06 PM

$ABCL

0 · Reply

Market Cap	1.40B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	13,960,601
Avg Vol	5,920,146
Day's Range	N/A - N/A
Shares Out	305.38M
Stochastic %K	71%
Beta	1.02
Analysts	Strong Sell
Price Target	$10.14